Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 7Lymphoma, Follicular 5Lymphoma, B-Cell 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, B-Cell, Marginal Zone 2Hematologic Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Plasmablastic Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematopoietic and Lymphoid System Neoplasm 1HIV Infections 1Composite Lymphoma 1Blast Crisis 1

Interventions

Etoposide 2prednylidene 1emvododstat 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Vorinostat 1Vincristine 1Rituximab 1Raltegravir Potassium 1Prednisone 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lenalidomide 1Immunohistochemistry 1Genes 1Gene Expression Profiling 1Doxorubicin 1Cytarabine 1Cyclophosphamide 1Carmustine 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × HIV Infections × CT-P10 × Clear all
NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡